ESPR - CIK 0001434868
The table below shows Esperion Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $156.16M | $92.45M | $86.06M | $114.63M | $144.72M | $189.30M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $132.35M | $118.98M | $107.75M | $81.29M | $67.82M | $60.36M |
| Inventory | $104.21M | $108.54M | $114.47M | $99.32M | $80.10M | $84.47M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $459.46M |
| $360.46M |
| $342.60M |
| $318.78M |
| $307.56M |
| $345.11M |
| Property, plant & equipment | $311.00K | $175.00K | $201.00K | $228.00K | $281.00K | $307.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $462.53M | $364.02M | $347.08M | $324.03M | $314.11M | $352.32M |
| Accounts payable | $68.41M | $77.51M | $74.70M | $71.99M | $34.86M | $47.67M |
| Total current liabilities | $300.36M | $359.03M | $298.80M | $270.97M | $165.87M | $175.34M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $770.46M | $815.38M | $780.59M | $750.24M | $684.32M | $696.54M |
| Retained earnings | -$1.65B | -$1.69B | -$1.65B | -$1.64B | -$1.58B | -$1.55B |
| Total equity | -$307.93M | -$451.36M | -$433.51M | -$426.21M | -$370.21M | -$344.22M |